tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Resmed Inc Officer Plans Sale of Common Stock Under Rule 144

Story Highlights
Resmed Inc Officer Plans Sale of Common Stock Under Rule 144

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an announcement.

Resmed Inc has filed a notice for the proposed sale of securities under Rule 144, with Brett Sandercock, an officer of the company, planning to sell 3,000 shares of common stock. The transaction, which involves securities acquired through restricted stock vesting and options granted, reflects a strategic decision by the officer, potentially impacting the company’s stock liquidity and market perception.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Resmed Inc operates within the healthcare industry, focusing on the development and manufacturing of equipment related to sleep disorders, such as sleep apnea. The company is known for its innovative solutions in respiratory care and has a significant market presence in providing devices and cloud-connected software applications that diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Average Trading Volume: 1,039,688

Technical Sentiment Signal: Buy

Current Market Cap: A$60.12B

Learn more about RMD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1